ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.04%
US Dollar vs MXN
18.0479
-0.47%
Brent Oil
84.685
0.79%
Bitcoin
60,918.38
-3.55%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sagiment Biosciences Inc (SGMT)

  7. Sagiment Biosciences Inc (SGMT) Noticias

SGMT

Sagiment Biosciences (SGMT)

Sagiment Biosciences Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SGMT
FechaHoraFuenteTítuloSímboloCompañía
13/06/202405:07Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SGMTSagiment Biosciences Inc
07/06/202415:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGMTSagiment Biosciences Inc
06/06/202405:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGMTSagiment Biosciences Inc
15/05/202406:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGMTSagiment Biosciences Inc
08/05/202415:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SGMTSagiment Biosciences Inc
25/03/202406:00GlobeNewswire Inc.Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsNASDAQ:SGMTSagiment Biosciences Inc
25/03/202405:15GlobeNewswire Inc.Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesNASDAQ:SGMTSagiment Biosciences Inc
29/02/202407:00GlobeNewswire Inc.Sagimet Biosciences to Participate in Two Upcoming Investor ConferencesNASDAQ:SGMTSagiment Biosciences Inc
14/02/202417:10Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SGMTSagiment Biosciences Inc
25/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGMTSagiment Biosciences Inc
25/01/202419:58GlobeNewswire Inc.Sagimet Biosciences Announces Pricing of Public Offering of Series A Common StockNASDAQ:SGMTSagiment Biosciences Inc
24/01/202405:08Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SGMTSagiment Biosciences Inc
23/01/202416:45GlobeNewswire Inc.Sagimet Biosciences Announces Proposed Public Offering of Series A Common StockNASDAQ:SGMTSagiment Biosciences Inc
23/01/202416:31Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SGMTSagiment Biosciences Inc
22/01/202406:00GlobeNewswire Inc.Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHNASDAQ:SGMTSagiment Biosciences Inc
04/12/202307:00GlobeNewswire Inc.Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst ClinicNASDAQ:SGMTSagiment Biosciences Inc
28/11/202307:00GlobeNewswire Inc.Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development SummitNASDAQ:SGMTSagiment Biosciences Inc
22/11/202307:00GlobeNewswire Inc.Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:SGMTSagiment Biosciences Inc
13/11/202307:00GlobeNewswire Inc.Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:SGMTSagiment Biosciences Inc
10/11/202307:30GlobeNewswire Inc.Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023NASDAQ:SGMTSagiment Biosciences Inc
24/10/202310:00GlobeNewswire Inc.Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023NASDAQ:SGMTSagiment Biosciences Inc
18/10/202315:05GlobeNewswire Inc.Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceNASDAQ:SGMTSagiment Biosciences Inc
27/09/202315:05GlobeNewswire Inc.Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent GlioblastomaNASDAQ:SGMTSagiment Biosciences Inc
21/08/202315:02GlobeNewswire Inc.Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:SGMTSagiment Biosciences Inc
15/08/202315:04GlobeNewswire Inc.Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public OfferingNASDAQ:SGMTSagiment Biosciences Inc
20/07/202315:05GlobeNewswire Inc.Sagimet Biosciences Announces Leadership ChangesNASDAQ:SGMTSagiment Biosciences Inc
13/07/202320:10GlobeNewswire Inc.Sagimet Biosciences Announces Pricing of Upsized Initial Public OfferingNASDAQ:SGMTSagiment Biosciences Inc
23/06/202301:30GlobeNewswire Inc.Sagimet Biosciences Presents Positive Phase 2b FASCINATE-2 Clinical Trial Interim Data for Denifanstat for the Treatment of NASH at EASL Congress 2023NASDAQ:SGMTSagiment Biosciences Inc
07/06/202308:00GlobeNewswire Inc.Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023NASDAQ:SGMTSagiment Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:SGMT

Su Consulta Reciente

USOTC
BCCMY
BAIC MTR (PK)
COIN
FITKRW
300FIT Network
NASDAQ
SVRE
SaverOne 2014
LATK
CUMSTARUSDT
CUMSTAR
NASDAQ
OXLC
Oxford Lane Capital
EU
COVAA
Covivio Hotels SACA 1.87...
USOTC
PRSTF
Prospect Resources (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados